市場調査レポート

商品コード

インドの新興感染症診断市場 (2023-2033年)：疫学・用途・技術・感染タイプ・疾患タイプ・エンドユーザーの分析・予測

India Emerging Infectious Disease Diagnostics Market: Focus on Epidemiology, Application, Technology, Type of Infection, Disease Type, and End User - Analysis and Forecast, 2023-2033

出版日: 2023年10月30日
発行: BIS Research
ページ情報: 英文 207 Pages
納期: 1～5営業日

カスタマイズ可能

価格

PDF and Excel (1-3 User License)

USD 1,975 285,664円

レポートPDFを3名様までご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストが可能です。PDFの印刷は可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。付属のExcelには、PDF内で使用されている数値データが含まれます。

PDF and Excel (Global License)

USD 3,225 466,464円

レポートPDFを同一企業の全世界の方にご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストが可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。付属のExcelには、PDF内で使用されている数値データが含まれます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=144.64円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

インドの新興感染症診断の市場規模は、2022年の3億3,910万米ドルから、予測期間中は10.29%のCAGRで推移し、2033年には9億8,270万米ドルの規模に成長すると予測されています。

インドの新興感染症診断市場は新興段階にあります。近年、特に次世代シーケンシングの登場やCOVID-19などの迅速検査への需要の高まりに伴い、診断方法の改善や革新が進んでいます。より速く、より効率的に、より費用対効果の高い診断を提供する新しい技術や機器は、市場を活性化させ、成長段階へと押し出す可能性があります。

用途別では、ラボ検査の部門が2022年の市場をリードしました。ラボ検査は、感染症の診断と管理において重要な役割を果たしています。また、技術別では、PCRの部門が2022年の市場をリードしました。PCRはDNAをさらに増幅し、少量の核酸でも分析できるため、現在では世界中の研究室で使用されています。

インドの新興感染症診断市場：概要

主要市場統計
予測期間	2023-2033年
2023年評価	3億6,910万米ドル
2033年予測	9億8,270万米ドル
CAGR	10.29%

当レポートでは、インドの新興感染症診断の市場を調査し、市場概要、市場成長への各種影響因子の分析、市場規模の推移・予測、各種区分別の詳細分析、競合情勢、主要企業の分析などをまとめています。

市場概要
- インドにおける感染症の疫学
- 感染症診断に最も推奨されるプラットフォーム
- 感染症診断のための新興技術のタイムライン
- 新興感染症診断技術の利点と限界
- ポイントオブケアの新興感染症診断の利点と限界

第5章インドの新興感染症診断市場：市場力学

影響分析
市場促進要因
市場抑制要因
市場機会

第6章インドの新興感染症診断市場：用途別

概要
ラボ検査
POC (ポイントオブケア) 検査

第7章インドの新興感染症診断市場：技術別

概要
ポリメラーゼ連鎖反応 (PCR)
- 逆転写PCR (RT-PCR)
- デジタルPCR
免疫診断
等温核酸増幅技術 (INAAT)
次世代シーケンス (NGS)
その他の技術

第8章インドの新興感染症診断市場：感染症タイプ別

概要
細菌性
ウイルス性
真菌性
その他 (寄生虫など)

第9章インドの新興感染症診断市場：疾患タイプ別

概要
呼吸器感染症
胃腸感染症
性感染症 (STI)
神経感染症
移植後の感染症
その他

第10章インドの新興感染症診断市場：エンドユーザー別

概要
病院・診療所
診断ラボ
その他

第11章市場：競合ベンチマーキングと企業プロファイル

競合情勢
市場シェア分析 (企業別)
企業プロファイル
- Abbott Laboratories
- Becton, Dickinson and Company
- bioMerieux S.A.
- Bio-Rad Laboratories, Inc.
- Co-Diagnostics, Inc.
- DANAHER CORPORATION
- DiaSorin S.p.A.
- F. Hoffmann-La Roche Ltd
- Hologic, Inc.
- QIAGEN N.V.
- Thermo Fisher Scientific Inc.
- Siemens Healthineers AG
新興企業のスナップショット
- Trivitron Healthcare
- Genes2Me
- CrisprBits
- D-NOME Pvt Ltd

図表

List of Figures

Figure 1: India Emerging Infectious Disease Diagnostics Market, $Million, 2022-2033
Figure 2: India Emerging Infectious Disease Diagnostics Market: Drivers, Restraints, and Opportunities
Figure 3: India Emerging Infectious Disease Diagnostics Market, Impact Analysis
Figure 4: India Emerging Infectious Disease Diagnostics Market (by Technology), Share (%), 2022 and 2033
Figure 5: India Emerging Infectious Disease Diagnostics Market (by Application), Share (%), 2022 and 2033
Figure 6: India Emerging Infectious Disease Diagnostics Market (by Type of Infection), Share (%), 2022 and 2033
Figure 7: India Emerging Infectious Disease Diagnostics Market (by Disease Type), Share (%), 2022 and 2033
Figure 8: Share of Key Developments, January 2019-June 2023
Figure 9: India Emerging Infectious Disease Diagnostics Market Segmentation
Figure 10: India Emerging Infectious Disease Diagnostics Market Research Methodology
Figure 11: Primary Research Methodology
Figure 12: Bottom-Up Approach (Segment-Wise Analysis)
Figure 13: Top-Down Approach (Segment-Wise Analysis)
Figure 14: India Emerging Infectious Disease Diagnostics Market, $Million, 2022-2033
Figure 15: Incidence of Influenza A and B, India, Thousand, 2022-2033
Figure 16: Diagnosis Rate of Influenza A and B, India, %, 2022-2033
Figure 17: Target Patient Pool of Influenza A and B, India, Thousand, 2022-2033
Figure 18: Incidence of RSV, India, Thousand, 2022-2033
Figure 19: Diagnosis Rate of RSV, India, %, 2022-2033
Figure 20: Target Patient Pool of RSV, India, 2022-2033
Figure 21: Incidence of Mycoplasma Infections, India, Thousand, 2022-2033
Figure 22: Diagnosis Rate of Mycoplasma Infections, India, %, 2022-2033
Figure 23: Target Patient Pool of Mycoplasma Infections, India, Thousand, 2022-2033
Figure 24: Incidence of Pertussis, India, 2022-2033
Figure 25: Diagnosis Rate of Pertussis, India, %, 2022-2033
Figure 26: Target Patient Pool of Pertussis, India, 2022-2033
Figure 27: Incidence of Hepatitis B Infection, India, Thousand, 2022-2033
Figure 28: Diagnosis Rate of Hepatitis B Infection, India, %, 2022-2033
Figure 29: Target Patient Pool of Hepatitis B Infection, India, Thousand, 2022-2033
Figure 30: Incidence of HIV-AIDS, India, Thousand, 2022-2033
Figure 31: Diagnosis Rate of HIV-AIDS, India, %, 2022-2033
Figure 32: Population Tested for HIV-AIDS, India, Thousand, 2022-2033
Figure 33: Incidence of HPV, India, Thousand, 2022-2033
Figure 34: Diagnosis Rate of HPV, India, %, 2022-2033
Figure 35: Target Patient Pool of HPV, India, Thousand, 2022-2033
Figure 36: Incidence of Herpes, India, Thousand, 2022-2033
Figure 37: Diagnosis Rate of Herpes, India, %, 2022-2033
Figure 38: Target Patient Pool of Herpes, India, Thousand, 2022-2033
Figure 39: Incidence of Gonorrhea, India, Thousand, 2022-2033
Figure 40: Diagnosis Rate of Gonorrhea, India, %, 2022-2033
Figure 41: Target Patient Pool of Gonorrhea, India, Thousand, 2022-2033
Figure 42: Incidence of Syphilis, India, Thousand, 2022-2033
Figure 43: Diagnosis Rate of Syphilis, India, %, 2022-2033
Figure 44: Target Patient Pool of Syphilis, India, Thousand, 2022-2033
Figure 45: Incidence of Colitis, India, Thousand, 2022-2033
Figure 46: Diagnosis Rate of Colitis, India, %, 2022-2033
Figure 47: Target Patient Pool of Colitis, India, Thousand, 2022-2033
Figure 48: Incidence of Peptic Ulcer, India, Thousand, 2022-2033
Figure 49: Diagnosis Rate of Peptic Ulcer, India, %, 2022-2033
Figure 50: Target Patient Pool of Peptic Ulcer, India, Thousand, 2022-2033
Figure 51: Incidence of Diarrhea, India, Thousand, 2022-2033
Figure 52: Diagnosis Rate of Diarrhea, India, %, 2022-2033
Figure 53: Target Patient Pool of Diarrhea, India, Thousand, 2022-2033
Figure 54: Incidence of Meningitis, India, Thousand, 2022-2033
Figure 55: Diagnosis Rate of Meningitis, India, %, 2022-2033
Figure 56: Target Patient Pool of Meningitis, India, Thousand, 2022-2033
Figure 57: Incidence of Encephalitis, India, Thousand, 2022-2033
Figure 58: Diagnosis Rate of Encephalitis, India, %, 2022-2033
Figure 59: Target Patient Pool of Encephalitis, India, Thousand, 2022-2033
Figure 60: Incidence of CMV Infection, India, 2022-2033
Figure 61: Diagnosis Rate of CMV Infection, India, %, 2022-2033
Figure 62: Target Patient Pool of CMV Infection, India, 2022-2033
Figure 63: Incidence of Sepsis, India, Thousand, 2022-2033
Figure 64: Diagnosis Rate of Sepsis, India, %, 2022-2033
Figure 65: Target Patient Pool of Sepsis, India, Thousand, 2022-2033
Figure 66: Microbe Resistance for Second Generation Antibiotics in India, %, 2018-2025
Figure 67: Preventive Measures to Limit AMR
Figure 68: Factors Contributing to Antimicrobial Resistance (AMR), India
Figure 69: Timeline of Emerging Technologies for Infectious Disease Diagnostics
Figure 70: Advantages of Emerging Infectious Disease Diagnostic Technologies
Figure 71: Limitations of Emerging Infectious Disease Diagnostic Technologies
Figure 72: Key Settings of POC Testing Deployment
Figure 73: India Emerging Infectious Disease Diagnostics Market, Impact Analysis
Figure 74: India Emerging Infectious Diseases Incidence, 2020-2022
Figure 75: Advantages of Point-of-Care Tests in Molecular Diagnostics
Figure 76: Advantages of INAAT over PCR
Figure 77: Advantages of Digital PCR over Quantitative Real-Time PCR
Figure 78: India Emerging Infectious Disease Diagnostics Market (by Application)
Figure 79: India Emerging Infectious Disease Diagnostics Market (by Application), Share (%), 2022 and 2033
Figure 80: India Emerging Infectious Disease Diagnostics Market (Laboratory Testing), $Million, 2022-2033
Figure 81: Laboratory Testing, Test Volume, Million, 2022-2033
Figure 82: India Emerging Infectious Disease Diagnostics Market (Point-of-Care Testing), $Million, 2022-2033
Figure 83: Point-of-Care Testing, Test Volume, Million, 2022-2033
Figure 84: India Emerging Infectious Disease Diagnostics Market (by Technology)
Figure 85: India Emerging Infectious Disease Diagnostics Market (by Technology), Share (%), 2022 and 2033
Figure 86: India Emerging Infectious Disease Diagnostics Market (PCR), $Million, 2022-2033
Figure 87: Polymerase Chain Reaction(PCR), Test Volume, Million, 2022-2033
Figure 88: India Emerging Infectious Disease Diagnostics Market (RT-PCR), $Million, 2022-2033
Figure 89: Reverse Transcription PCR (RT-PCR), Test Volume, Thousand, 2022-2033
Figure 90: India Emerging Infectious Disease Diagnostics Market (Digital PCR), $Million, 2022-2033
Figure 91: Digital PCR, Test Volume, Thousand, 2022-2033
Figure 92: India Emerging Infectious Disease Diagnostics Market (Immunodiagnostics), $Million, 2022-2033
Figure 93: Immunodiagnostics, Test Volume, Million, 2022-2033
Figure 94: India Emerging Infectious Disease Diagnostics Market (Isothermal Nucleic Acid Amplification Technology (INAAT)), $Million, 2022-2033
Figure 95: Isothermal Nucleic Acid Amplification Technology (INAAT), Test Volume, Million, 2022-2033
Figure 96: India Emerging Infectious Disease Diagnostics Market (Next-Generation Sequencing (NGS)), $Million, 2022-2033
Figure 97: Next-Generation Sequencing (NGS), Test Volume, Million, 2022-2033
Figure 98: India Emerging Infectious Disease Diagnostics Market (Other Technologies), $Million, 2022-2033
Figure 99: Other Technologies, Test Volume, Million, 2022-2033
Figure 100: India Emerging Infectious Disease Diagnostics Market (by Type of Infection)
Figure 101: India Emerging Infectious Disease Diagnostics Market (by Type of Infection), Share (%), 2022 and 2033
Figure 102: India Emerging Infectious Disease Diagnostics Market (Bacterial), $Million, 2022-2033
Figure 103: Bacterial Infections, Test Volume, Million, 2022-2033
Figure 104: India Emerging Infectious Disease Diagnostics Market (Viral), $Million, 2022-2033
Figure 105: Viral Infections, Test Volume, Million, 2022-2033
Figure 106: India Emerging Infectious Disease Diagnostics Market (Fungal), $Million, 2022-2033
Figure 107: Fungal Infections, Test Volume, Million, 2022-2033
Figure 108: India Emerging Infectious Disease Diagnostics Market (Other Infections), $Million, 2022-2033
Figure 109: Other Infections, Test Volume, Million, 2022-2033
Figure 110: India Emerging Infectious Disease Diagnostics Market (by Disease Type)
Figure 111: India Emerging Infectious Disease Diagnostics Market (by Disease Type), Share (%), 2022 and 2033
Figure 112: India Emerging Infectious Disease Diagnostics Market (Respiratory Infections), $Million, 2022-2033
Figure 113: Respiratory Infections, Test Volume, Million, 2022-2033
Figure 114: India Emerging Infectious Disease Diagnostics Market (Gastrointestinal Infections), $Million, 2022-2033
Figure 115: Gastrointestinal Infections, Test Volume, Million, 2022-2033
Figure 116: India Emerging Infectious Disease Diagnostics Market (Sexually Transmitted Infections (STIs)), $Million, 2022-2033
Figure 117: Sexually Transmitted Infections, Test Volume, Million, 2022-2033
Figure 118: India Emerging Infectious Disease Diagnostics Market (Neurological Infections), $Million, 2022-2033
Figure 119: Neurological Infections, Test Volume, Million, 2022-2033
Figure 120: India Emerging Infectious Disease Diagnostics Market (Post-Transplant Infections), $Million, 2022-2033
Figure 121: Post-Transplant Infections, Test Volume, Million, 2022-2033
Figure 122: India Emerging Infectious Disease Diagnostics Market (Other Infections), $Million, 2022-2033
Figure 123: Other Infections, Test Volume, Million, 2022-2033
Figure 124: India Emerging Infectious Disease Diagnostics Market (by End User)
Figure 125: India Emerging Infectious Disease Diagnostics Market (by End User), Share (%), 2022 and 2033
Figure 126: India Emerging Infectious Disease Diagnostics Market (Hospitals and Clinics), $Million, 2022-2033
Figure 127: Hospitals and Clinics, Test Volume, Million, 2022-2033
Figure 128: India Emerging Infectious Disease Diagnostics Market (Diagnostic Laboratories), $Million, 2022-2033
Figure 129: Diagnostic Laboratories, Test Volume, Million, 2022-2033
Figure 130: India Emerging Infectious Disease Diagnostics Market (Other End Users), $Million, 2022-2033
Figure 131: Other End Users, Test Volume, Million, 2022-2033
Figure 132: Share of Key Developments, January 2019-June 2023
Figure 133: Number of Mergers and Acquisitions (by Company), January 2019-June 2023
Figure 134: Share of Synergistic Activities (by Company), January 2019-June 2023
Figure 135: Number of Business Expansions and Funding Activities (by Company), January 2019-June 2023
Figure 136: Number of Product Launches/Upgradations/Approvals (by Company), January 2019-June 2023
Figure 137: Market Share Analysis for India Emerging Infectious Disease Diagnostics Market (by Company), 2022
Figure 138: India Emerging Infectious Disease Diagnostics Market, Total Number of Companies Profiled
Figure 139: Abbott Laboratories: Product Portfolio
Figure 140: Abbott Laboratories: Overall Financials, $Million, 2020-2022
Figure 141: Abbott Laboratories: Revenue (by Segment), $Million, 2020-2022
Figure 142: Abbott Laboratories: Revenue (by Region), $Million, 2020-2022
Figure 143: Abbott Laboratories: R&D Expenditure, $Million, 2020-2022
Figure 144: Becton, Dickinson and Company (BD): Product Portfolio
Figure 145: Becton, Dickinson and Company: Overall Financials, $Million, 2020-2022
Figure 146: Becton, Dickinson and Company: Revenue (by Segment), $Million, 2020-2022
Figure 147: Becton, Dickinson and Company: Revenue (by Region), $Million, 2020-2022
Figure 148: Becton, Dickinson and Company: R&D Expenditure, $Million, 2020-2022
Figure 149: bioMerieux S.A.: Product Portfolio
Figure 150: bioMerieux S.A.: Overall Financials, $Million, 2020-2022
Figure 151: bioMerieux S.A.: Revenue (by Segment), $Million, 2020-2022
Figure 152: bioMerieux S.A.: Revenue (by Region), $Million, 2020-2022
Figure 153: bioMerieux S.A.: R&D Expenditure, $Million, 2020-2022
Figure 154: Bio-Rad Laboratories, Inc.: Product Portfolio
Figure 155: Bio-Rad Laboratories, Inc.: Overall Financials, $Million, 2020-2022
Figure 156: Bio-Rad Laboratories, Inc.: Revenue (by Segment), $Million, 2020-2022
Figure 157: Bio-Rad Laboratories, Inc.: Revenue (by Region), $Million, 2020-2022
Figure 158: Bio-Rad Laboratories, Inc.: R&D Expenditure, $Million, 2020-2022
Figure 159: Co-Diagnostics, Inc.: Product Portfolio
Figure 160: DANAHER CORPORATION: Product Portfolio
Figure 161: DANAHER CORPORATION: Overall Financials, $Million, 2020-2022
Figure 162: DANAHER CORPORATION: Revenue (by Segment), $Million, 2020-2022
Figure 163: DANAHER CORPORATION: Revenue (by Region), $Million, 2020-2022
Figure 164: DANAHER CORPORATION: R&D Expenditure, $Million, 2020-2022
Figure 165: DiaSorin S.p.A.: Product Portfolio
Figure 166: DiaSorin S.p.A.: Overall Financials, $Million, 2021-2022
Figure 167: DiaSorin S.p.A.: Revenue (by Region), $Million, 2021-2022
Figure 168: DiaSorin S.p.A.: R&D Expenditure, $Million, 2021-2022
Figure 169: F. Hoffmann-La Roche Ltd: Product Portfolio
Figure 170: F. Hoffmann-La Roche Ltd: Overall Financials, 2020-2022
Figure 171: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2020-2022
Figure 172: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2020-2022
Figure 173: Hologic, Inc.: Product Portfolio
Figure 174: Hologic, Inc.: Overall Financials, $Million, 2020-2022
Figure 175: Hologic, Inc.: Revenue (by Segment), $Million, 2020-2022
Figure 176: Hologic, Inc.: Revenue (by Region), $Million, 2020-2022
Figure 177: Hologic, Inc.: R&D Expenditure, $Million, 2020-2022
Figure 178: QIAGEN N.V.: Product Portfolio
Figure 179: QIAGEN N.V.: Overall Financials, $Million, 2020-2022
Figure 180: QIAGEN N.V.: Revenue (by Segment), $Million, 2020-2022
Figure 181: QIAGEN N.V.: Revenue (by Region), $Million, 2020-2022
Figure 182: QIAGEN N.V.: R&D Expenditure, $Million, 2020-2022
Figure 183: Thermo Fisher Scientific Inc.: Product Portfolio
Figure 184: Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2020-2022
Figure 185: Thermo Fisher Scientific Inc.: Revenue (by Segment), $Million, 2020-2022
Figure 186: Thermo Fisher Scientific Inc.: Revenue (by Region), $Million, 2020-2022
Figure 187: Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2020-2022
Figure 188: Siemens Healthineers AG: Product Portfolio
Figure 189: Siemens Healthineers AG: Overall Financials, $Million, 2020-2022
Figure 190: Siemens Healthineers AG: Revenue (by Segment), $Million, 2020-2022
Figure 191: Siemens Healthineers AG: Revenue (by Region), $Million, 2020-2022
Figure 192: Siemens Healthineers AG: R&D Expenditure, $Million, 2020-2022

List of Tables

Table 1: At-Home COVID-19 Kits Approved for Commercial Use by ICMR
Table 2: Commercially Available RT-PCR Kits
Table 3: Commercially Available NGS Panels/Kits

Product Code: BHP1447SA

“The India Emerging Infectious Disease Diagnostics Market to Reach $982.7 Million by 2033.”

India Emerging Infectious Disease Diagnostics Market Overview

KEY MARKET STATISTICS
Forecast Period	2023 - 2033
2023 Evaluation	$369.1 Million
2033 Forecast	$982.7 Million
CAGR	10.29%

The India emerging infectious disease diagnostics market is projected to experience substantial growth over the forecast period 2023-2033. Moreover, the market value for 2022 was estimated to be $339.1 million and is expected to reach $982.7 million by 2033, showcasing a CAGR of 10.29% during the forecast period.

Market Lifecycle Stage

The India emerging infectious disease diagnostics market is in an emerging phase. Recent years have seen improvements and innovations in diagnostic methods, particularly with the advent of next-generation sequencing and the growing demand for rapid testing (such as in the case of the COVID-19 pandemic). New technologies and devices that offer faster, more efficient, or more cost-effective extraction could rejuvenate the market and push it back toward a growth phase.

Industry Impact

The India emerging infectious disease diagnostics market has proven to be a cornerstone in the evolution of modern biotechnology, clinical diagnostics, and research of different pathogens. Infectious disease diagnostics have a significant impact on various aspects of healthcare and public health. Here are some key impacts:

Accurate and Timely Diagnosis: Infectious disease diagnostics enable healthcare providers to accurately identify the causative agents of infections, leading to timely and appropriate treatment. Early diagnosis helps improve patient outcomes, reduce morbidity and mortality rates, and prevent the spread of infectious diseases.

Effective Patient Management: Diagnostic tests provide critical information for healthcare providers to guide patient management strategies. These tests help determine the most effective treatment options, including the selection of appropriate antimicrobial therapies and the implementation of infection control measures. This leads to better patient care and improved healthcare outcomes.

Public Health Surveillance and Outbreak Control: Infectious disease diagnostics play a crucial role in public health surveillance. By identifying and monitoring infectious agents, diagnostic tests contribute to the detection and tracking of disease outbreaks. This information helps public health authorities implement timely interventions, such as contact tracing, isolation measures, and targeted vaccination campaigns, to control the spread of infections.

Research and Development: Infectious disease diagnostics drive research and development efforts to improve existing diagnostic methods and develop new technologies. Ongoing advancements in diagnostics contribute to the discovery of novel biomarkers, the enhancement of diagnostic accuracy and sensitivity, and the integration of innovative approaches such as molecular techniques, biosensors, and artificial intelligence.

Market Segmentation:

Segmentation 1: by Application

Laboratory Testing
Point-of-Care Testing

Laboratory Testing to Dominate the India Emerging Infectious Disease Diagnostics Market (by Application)

Based on application, the laboratory testing segment dominated the India emerging infectious disease diagnostics market in FY2022. Laboratory testing plays a crucial role in the diagnosis and management of infectious diseases. It involves the analysis of patient samples, such as blood, urine, sputum, or tissue, to detect the presence of infectious agents. Microbiological culture is a common technique that involves incubating patient samples on specific growth media to isolate and identify bacteria, fungi, or parasites, which can then be visualized through microscopy.

Segmentation 2: by Technology

Polymerase Chain Reaction (PCR)
Isothermal Nucleic Acid Amplification Technology (INAAT)
Next-Generation Sequencing (NGS)
Immunodiagnostics
Other Technologies

PCR to Dominate the India Emerging Infectious Disease Diagnostics Market (by Technology)

Based on technology, the India emerging infectious disease diagnostics market was dominated by the PCR segment in FY2022. Nowadays, PCR is usually used in several laboratories around the world, as it amplifies DNA further, allowing the analysis of even small amounts of nucleic acid. With growing technological advancements in molecular biology techniques, PCR has been utilized in several fields, including disease diagnosis, DNA profiling, precision medicine, and gene expression.

Next-generation sequencing (NGS) has revolutionized infectious disease diagnosis by enabling comprehensive and high-throughput analysis of pathogen genomes. Whole genome sequencing (WGS) allows the sequencing of entire pathogen genomes, providing detailed information about genetic variations, antimicrobial resistance genes, and virulence factors. It can identify and characterize pathogens, track outbreaks, and analyze their evolutionary patterns.

Other emerging technologies anticipated to register significant growth include technologies such as digital PCR, INAAT, and clustered regularly interspaced short palindromic repeats (CRISPR).

Digital PCR is an advanced molecular diagnostic technique used for infectious disease diagnostics. It enables the absolute quantification of target nucleic acids by partitioning the PCR reaction into thousands of individual reactions.
INAAT has emerged as a valuable tool for infectious disease diagnostics. INAAT includes technologies such as loop-mediated isothermal amplification (LAMP) and recombinase polymerase amplification (RPA), which enable rapid and sensitive detection of pathogens without the need for complex equipment or multiple temperature cycles.
CRISPR is a relatively new technology, and while it has been leveraged for gene editing and therapeutic purposes ever since the invention of CRISPR/Cas9 gene editing in 2011, it was only in 2016 that CRISPR-Cas systems were first developed to identify nucleic acids for molecular diagnostics.

Segmentation 3: by Type of Infection

Bacterial
Viral
Fungal
Other Infections (Parasitic etc)

Bacterial and Viral Segments to Dominate the India Emerging Infectious Disease Diagnostics Market (by Type of Infection)

Based on type of infection, bacterial infectious disease diagnosis involves various methods and techniques to identify the presence of bacterial pathogens in clinical samples. Some of the common bacterial infections include respiratory infections such as tuberculosis and streptococcal infections and sexually transmitted infections (STIs) such as chlamydia, gonorrhea, and syphilis.

Viruses have the ability to mutate and, therefore, can lead to the re-emergence of diseases even after one form of the virus has been eradicated or managed. Molecular diagnostic companies are therefore focused on developing tests that can detect a wide range of viruses. Some of the common infections caused by viruses include influenza, genital herpes, COVID-19, hepatitis, mumps, rubella, gastroenteritis, Zika disease, and ebola disease, among others.

Segmentation 4: by Disease Type

Respiratory Infections
Gastrointestinal Infections
Sexually Transmitted Infections (STIs)
Neurological Infections
Post-Transplant Infections
Other Infections

Respiratory Infections to Dominate the India Emerging Infectious Disease Diagnostics Market (by Disease Type)

A vast majority of molecular diagnostic companies offer tests for various kinds of bacteria and viruses responsible for causing respiratory infections. Moreover, the COVID-19 pandemic led to the development of a wide range of tests employing conventional technologies such as reverse transcriptase PCR (RT-PCR) and even leveraging emerging technologies such as RT-LAMP and CRISPR. Several companies now offer multiplex assays that test for influenza A, influenza B, respiratory syncytial virus (RSV), and SARS-CoV-2 virus.

Segmentation 5: by End User

Hospitals and Clinics
Diagnostic Laboratories
Other End Users

Hospitals and Clinics and Diagnostic Laboratories to Dominate the India Emerging Infectious Disease Diagnostics Market (by End User)

Based on end users, the hospitals and clinics and diagnostic laboratories segments accounted for the largest share of the India emerging infectious disease diagnostics market in FY2022. Hospitals and clinics play a critical role in the field of infectious disease diagnostics, serving as important centers for patient evaluation and testing. In addition to point-of-care testing (POCT), which provides immediate results for rapid diagnosis and management, hospitals and clinics may also rely on laboratory testing for comprehensive analysis. Some healthcare facilities have on-site laboratories equipped with state-of-the-art diagnostic technologies, while others collaborate with external diagnostic laboratories for specialized testing. These laboratory facilities employ various methods, including molecular techniques such as PCR and sequencing, serological assays, and culture-based methods to identify and characterize infectious agents accurately.

Recent Developments in the India Emerging Infectious Disease Diagnostics Market

In February 2023, Thermo Fisher Scientific Inc. and Mylab announced a pact on test kits for infectious diseases.

In February 2023, Biotech startup CrisprBits raised $250,000 in a pre-seed funding round to support the development and commercialization of its CRISPR-based tests.

In February 2023, the Food and Drug Administration (FDA) authorized the Xpert Mpox test by Cepheid (parent: DANAHER CORPORATION) for emergency use.

In August 2022, Bio-Rad Laboratories, Inc. acquired Curiosity Diagnostics to gain access to PCR ONE, a technology being developed by Curiosity Diagnostics, which can quickly detect a broad range of pathogens.

In June 2021, Hologic, Inc. completed the acquisition of Mobidiag to expand its capabilities in molecular diagnostics.

In January 2023, CrisprBits developed India's first CRISPR-based SARS-CoV-2 test with Omicron detection.

In March 2023, an India-based startup, Mylab Discovery Solutions Pvt. Ltd., entered into a joint venture with AstraGene LLC, the U.A.E.'s first molecular diagnostics manufacturing company to develop molecular diagnostics in the U.A.E. and Kuwait.

In November 2022, Bio-Rad Laboratories, Inc. and NuProbe entered into an exclusive licensing agreement for digital PCR applications.

Demand - Drivers, Restraints, and Opportunities

Market Drivers:

Rising Incidence of Emerging Infectious Diseases in India: The incidence of emerging infectious diseases in India has witnessed a steady rise in recent years, contributing significantly to the expansion of the country's emerging infectious disease diagnostics market. India emerging infectious disease diagnostics market has experienced substantial growth due to multiple factors. In addition to increased awareness and government initiatives, the country's past encounters with outbreaks such as Zika, Nipah, and the COVID-19 pandemic have underscored the critical importance of preparedness. As a result, hospitals, laboratories, and healthcare institutions have been channeling resources into advanced diagnostic technologies to detect emerging infectious diseases swiftly and accurately.

Market Restraints:

Inadequate Healthcare Infrastructure and Facilities: The India emerging infectious disease diagnostics market faces significant constraints due to inadequate healthcare infrastructure and facilities. These challenges could have a substantial impact on the ability to effectively diagnose and manage infectious diseases in the country.

For instance, the presence of limited healthcare infrastructure in many parts of India, particularly in rural and remote areas, poses a significant hurdle. These regions often lack well-equipped laboratories and diagnostic facilities, making it difficult to conduct timely and accurate diagnostic tests. As a result, individuals in these underserved areas may not have access to the diagnostics they need, which can lead to delayed diagnoses and increased disease transmission.

Market Opportunities:

Development of Technologically Advanced Platforms in India for Diagnosis: The development of technologically advanced diagnostic platforms in India represents a significant opportunity for players in the emerging infectious disease diagnostics market. The development of advanced diagnostic platforms can help address some of the existing constraints in the healthcare system, such as inadequate healthcare infrastructure and limited access to diagnostics in rural and remote areas.

These advancements include the development of molecular diagnostics, point-of-care testing, immunoassays, and automated systems, among others. These advancements also provide rapid and accurate results, enabling healthcare professionals to make timely treatment decisions.

How can this report add value to an organization?

Workflow/Innovation Strategy: The India emerging infectious disease diagnostics market has been extensively segmented on the basis of various categories, such as application, technology, type of infection, disease type, end user, and region. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Growth/Marketing Strategy: In the India emerging infectious disease diagnostics market product launches, upgradations, and approvals accounted for the maximum number of key developments, i.e., over 75.89% of the total developments in the India emerging infectious disease diagnostics market, as of September 2023.

Competitive Strategy: The India emerging infectious disease diagnostics market is fragmented with several established as well as emerging players. Key players in the India emerging infectious disease diagnostics market analyzed and profiled in the study involve established players that offer various kinds of molecular diagnostic tests for infectious diseases.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

The base year considered for the calculation of the market size is 2022. The historical year analysis has been done from FY2020 to FY2021, and the market size has been calculated for FY2022 and projected for the period 2023-2033.
The geographical distribution of the market revenue is estimated to be the same as the company's net revenue distribution. All the numbers are adjusted off to two digits after decimal for report presentation reasons. However, the real figures have been utilized for compound annual growth rate (CAGR) estimation. CAGR is calculated from 2023 to 2033.
The market has been mapped based on different types of products available in the market and based on several indications. All the key companies that have a significant number of offerings to the India emerging infectious disease diagnostics market have been considered and profiled in the report.
In the study, the primary respondent's verification has been considered to finalize the estimated market for the India emerging infectious disease diagnostics market.
The latest annual reports of each market player have been taken into consideration for market revenue calculation.
Market strategies and developments of key players have been considered for the calculation of sub-segment split.
The base currency considered for the market analysis is US$. Currencies other than the US$ have been converted to the US$ for all statistical calculations, considering the average conversion rate for that particular year. The currency conversion rate has been taken from the historical exchange rate of the Oanda website or from the annual reports of the respective company if stated.

Primary Research

The key data points taken from the primary sources include:

Validation and triangulation of all the numbers and graphs
Validation of the report's segmentation and key qualitative findings
Understanding of the numbers of the various markets for market type

Secondary Research

Open Sources

National Center for Biotechnology Information (NCBI), PubMed, Science Direct, World Bank Group, Organisation for Economic Co-operation and Development (OECD), Centers for Disease Control and Prevention (CDC), Global Burden Disease (GBD), World Health Organization (WHO), and Indian Council of Medical Research (ICMR)
Annual reports, SEC filings, and investor presentations of the leading market players
Company websites and detailed study of their portfolio
Gold standard magazines, journals, whitepapers, press releases, and news articles
Databases

The key data points taken from the secondary sources include:

Segmentations, split-ups, and percentage shares
Data for market value
Key industry trends of the top players in the market
Qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
Quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis

Infectious disease diagnostics encompass a range of methods and techniques used to identify and detect infectious agents in individuals suspected of having an infection. These diagnostics play a vital role in timely diagnosis and accuracy, enabling appropriate treatment decisions and public health interventions.

There are two major approaches in the field; one is microbiological culture, which is a fundamental approach in which patient specimens are cultured on specialized growth media to isolate and identify specific pathogens. This technique allows for the determination of the causative organism and the assessment of its antimicrobial susceptibility. Molecular diagnostics, another important approach, utilizes techniques such as polymerase chain reaction (PCR) and nucleic acid amplification tests (NAATs) to detect the genetic material of the infectious agent. This enables highly sensitive and specific identification of pathogens, even at low concentrations.

Some of the prominent companies in this market are:

Abbott Laboratories
Becton, Dickinson and Company
bioMerieux S.A.
Bio-Rad Laboratories, Inc.
Co-Diagnostics, Inc.
DANAHER CORPORATION

DiaSorin S.p.A.
F. Hoffmann-La Roche Ltd
Hologic, Inc.
QIAGEN N.V.
Thermo Fisher Scientific Inc.
Siemens Healthineers AG

Companies that are not a part of the aforementioned pool have been well represented across different sections of the report (wherever applicable).

1 Product Definition

1.1 Inclusion and Exclusion Criteria

2 Market Scope

2.1 Scope of the Study
2.2 Key Questions Answered in the Report

3 Research Methodology

4 Market Overview

4.1 Market Overview
- 4.1.1 Epidemiology of Infectious Diseases in India
  - 4.1.1.1 Respiratory Infections
    - 4.1.1.1.1 Influenza A and B
      - 4.1.1.1.1.1 Incidence
      - 4.1.1.1.1.2 Diagnosis Rate
      - 4.1.1.1.1.3 Target Patient Pool
    - 4.1.1.1.2 Respiratory Syncytial Virus
      - 4.1.1.1.2.1 Incidence
      - 4.1.1.1.2.2 Diagnosis Rate
      - 4.1.1.1.2.3 Target Patient Pool
    - 4.1.1.1.3 Mycoplasma Infections
      - 4.1.1.1.3.1 Incidence
      - 4.1.1.1.3.2 Diagnosis Rate
      - 4.1.1.1.3.3 Target Patient Pool
    - 4.1.1.1.4 Pertussis
      - 4.1.1.1.4.1 Incidence
      - 4.1.1.1.4.2 Diagnosis Rate
      - 4.1.1.1.4.3 Target Patient Pool
  - 4.1.1.2 Sexual Transmitted Infections (STIs)
    - 4.1.1.2.1 Hepatitis B Infection
      - 4.1.1.2.1.1 Incidence
      - 4.1.1.2.1.2 Diagnosis Rate
      - 4.1.1.2.1.3 Target Patient Pool
    - 4.1.1.2.2 HIV-AIDS
      - 4.1.1.2.2.1 Incidence
      - 4.1.1.2.2.2 Diagnosis Rate
      - 4.1.1.2.2.3 Population Tested for HIV
    - 4.1.1.2.3 HPV Infection
      - 4.1.1.2.3.1 Incidence
      - 4.1.1.2.3.2 Diagnosis Rate
      - 4.1.1.2.3.3 Target Patient Pool
    - 4.1.1.2.4 Herpes
      - 4.1.1.2.4.1 Incidence
      - 4.1.1.2.4.2 Diagnosis Rate
      - 4.1.1.2.4.3 Target Patient Pool
    - 4.1.1.2.5 Gonorrhea
      - 4.1.1.2.5.1 Incidence
      - 4.1.1.2.5.2 Diagnosis Rate
      - 4.1.1.2.5.3 Target Patient Pool
    - 4.1.1.2.6 Syphilis
      - 4.1.1.2.6.1 Incidence
      - 4.1.1.2.6.2 Diagnosis Rate
      - 4.1.1.2.6.3 Target Patient Pool
  - 4.1.1.3 Gastrointestinal Infections
    - 4.1.1.3.1 Colitis
      - 4.1.1.3.1.1 Incidence
      - 4.1.1.3.1.2 Diagnosis Rate
      - 4.1.1.3.1.3 Target Patient Pool
    - 4.1.1.3.2 Peptic Ulcer
      - 4.1.1.3.2.1 Incidence
      - 4.1.1.3.2.2 Diagnosis Rate
      - 4.1.1.3.2.3 Target Patient Pool
    - 4.1.1.3.3 Diarrhea
      - 4.1.1.3.3.1 Incidence
      - 4.1.1.3.3.2 Diagnosis Rate
      - 4.1.1.3.3.3 Target Patient Pool
  - 4.1.1.4 Neurological Infections
    - 4.1.1.4.1 Meningitis
      - 4.1.1.4.1.1 Incidence
      - 4.1.1.4.1.2 Diagnosis Rate
      - 4.1.1.4.1.3 Target Patient Pool
    - 4.1.1.4.2 Encephalitis
      - 4.1.1.4.2.1 Incidence
      - 4.1.1.4.2.2 Diagnosis Rate
      - 4.1.1.4.2.3 Target Patient Pool
  - 4.1.1.5 Post-Transplant Infections
    - 4.1.1.5.1 CMV Infection
      - 4.1.1.5.1.1 Incidence
      - 4.1.1.5.1.2 Diagnosis Rate
      - 4.1.1.5.1.3 Target Patient Pool
  - 4.1.1.6 Sepsis
  - 4.1.1.7 Antimicrobial Resistance (AMR)
    - 4.1.1.7.1 Microbe Resistance
    - 4.1.1.7.2 Key Causative Agents
    - 4.1.1.7.3 Preventive Measures to Limit AMR
    - 4.1.1.7.4 Challenges
- 4.1.2 Most Preferred Platforms for Infectious Disease Diagnosis
  - 4.1.2.1 Rapid Antigen Test (RAT)
  - 4.1.2.2 Polymerase Chain Reaction (PCR)
  - 4.1.2.3 Next-Generation Sequencing (NGS)
- 4.1.3 Timeline of Emerging Technologies for Infectious Disease Diagnostics
- 4.1.4 Advantages and Limitations of Emerging Infectious Disease Diagnostic Technologies
- 4.1.5 Advantages and Limitations of Point-of-Care Emerging Infectious Disease Diagnostics

5 India Emerging Infectious Disease Diagnostics Market: Market Dynamics

5.1 Impact Analysis
5.2 Market Drivers
- 5.2.1 Rising Incidence of Emerging Infectious Diseases in India
- 5.2.2 Increasing Adoption of Point-of-Care Testing in India
- 5.2.3 Initiatives by Government and Organizations to Increase Awareness
5.3 Market Restraints
- 5.3.1 Inadequate Healthcare Infrastructure and Facilities
- 5.3.2 Lack of Skilled Personnel in Specialized Areas of Infectious Disease Control
5.4 Market Opportunities
- 5.4.1 Development of Technologically Advanced Platforms in India for Diagnosis
  - 5.4.1.1 Isothermal Nucleic Acid Amplification Techniques (INAATs)
  - 5.4.1.2 Digital PCR (dPCR)
    - 5.4.1.2.1 Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Technologies

6 India Emerging Infectious Disease Diagnostics Market (by Application), $Million, 2022-2033

6.1 Overview
6.2 Laboratory Testing
6.3 Point-of-Care Testing

7 India Emerging Infectious Disease Diagnostics Market (by Technology), $Million, 2022-2033

7.1 Overview
7.2 Polymerase Chain Reaction (PCR)
- 7.2.1 Reverse Transcription PCR (RT-PCR)
- 7.2.2 Digital PCR
7.3 Immunodiagnostics
7.4 Isothermal Nucleic Acid Amplification Technology (INAAT)
7.5 Next-Generation Sequencing (NGS)
7.6 Other Technologies

8 India Emerging Infectious Disease Diagnostics Market (by Type of Infection), $Million, 2022-2033

8.1 Overview
8.2 Bacterial
8.3 Viral
8.4 Fungal
8.5 Other Infections (Parasitic etc.)

9 India Emerging Infectious Disease Diagnostics Market (by Disease Type), 2023-2033

9.1 Overview
9.2 Respiratory Infections
9.3 Gastrointestinal Infections
9.4 Sexually Transmitted Infections (STIs)
9.5 Neurological Infections
9.6 Post-Transplant Infections
9.7 Other Infections

10 India Emerging Infectious Disease Diagnostics Market (by End User), $Million, 2022-2033

10.1 Overview
10.2 Hospitals and Clinics
10.3 Diagnostic Laboratories
10.4 Other End Users

11 Markets - Competitive Benchmarking & Company Profiles

11.1 Competitive Landscape
- 11.1.1 Overview
- 11.1.2 Corporate Strategies
  - 11.1.2.1 Mergers and Acquisitions
  - 11.1.2.2 Synergistic Activities
  - 11.1.2.3 Business Expansions and Funding
- 11.1.3 Business Strategies
  - 11.1.3.1 Product Launches/Upgradations/Approvals
11.2 Market Share Analysis (by Company)
11.3 Company Profiles
- 11.3.1 Abbott Laboratories
  - 11.3.1.1 Company Overview
  - 11.3.1.2 Role of Abbott Laboratories in the India Emerging Infectious Disease Diagnostics Market
  - 11.3.1.3 Financials
  - 11.3.1.4 Recent Developments
  - 11.3.1.5 Analyst Perspective
- 11.3.2 Becton, Dickinson and Company
  - 11.3.2.1 Company Overview
  - 11.3.2.2 Role of Becton, Dickinson and Company in the India Emerging Infectious Disease Diagnostics Market
  - 11.3.2.3 Financials
  - 11.3.2.4 Recent Developments
  - 11.3.2.5 Analyst Perspective
- 11.3.3 bioMerieux S.A.
  - 11.3.3.1 Company Overview
  - 11.3.3.2 Role of bioMerieux S.A. in the India Emerging Infectious Disease Diagnostics Market
  - 11.3.3.3 Financials
  - 11.3.3.1 Recent Developments
  - 11.3.3.2 Analyst Perspective
- 11.3.4 Bio-Rad Laboratories, Inc.
  - 11.3.4.1 Company Overview
  - 11.3.4.2 Role of Bio-Rad Laboratories, Inc. in the India Emerging Infectious Disease Diagnostics Market
  - 11.3.4.3 Financials
  - 11.3.4.4 Recent Developments
  - 11.3.4.5 Analyst Perspective
- 11.3.5 Co-Diagnostics, Inc.
  - 11.3.5.1 Company Overview
  - 11.3.5.2 Role of Co-Diagnostics, Inc. in the India Emerging Infectious Disease Diagnostics Market
  - 11.3.5.3 Recent Developments
  - 11.3.5.4 Analyst Perspective
- 11.3.6 DANAHER CORPORATION
  - 11.3.6.1 Company Overview
  - 11.3.6.2 Role of DANAHER CORPORATION in the India Emerging Infectious Disease Diagnostics Market
  - 11.3.6.3 Financials
  - 11.3.6.4 Recent Developments
  - 11.3.6.5 Analyst Perspective
- 11.3.7 DiaSorin S.p.A.
  - 11.3.7.1 Company Overview
  - 11.3.7.2 Role of DiaSorin S.p.A. in the India Emerging Infectious Disease Diagnostics Market
  - 11.3.7.3 Financials
  - 11.3.7.4 Recent Developments
  - 11.3.7.5 Analyst Perspective
- 11.3.8 F. Hoffmann-La Roche Ltd
  - 11.3.8.1 Company Overview
  - 11.3.8.2 Role of F. Hoffmann-La Roche Ltd in the India Emerging Infectious Disease Diagnostics Market
  - 11.3.8.3 Financials
  - 11.3.8.4 Recent Developments
  - 11.3.8.5 Analyst Perspective
- 11.3.9 Hologic, Inc.
  - 11.3.9.1 Company Overview
  - 11.3.9.2 Role of Hologic, Inc. in the India Emerging Infectious Disease Diagnostics Market
  - 11.3.9.3 Financials
  - 11.3.9.4 Recent Developments
  - 11.3.9.5 Analyst Perspective
- 11.3.10 QIAGEN N.V.
  - 11.3.10.1 Company Overview
  - 11.3.10.2 Role of QIAGEN N.V. in the India Emerging Infectious Disease Diagnostics Market
  - 11.3.10.3 Financials
  - 11.3.10.4 Recent Developments
  - 11.3.10.5 Analyst Perspective
- 11.3.11 Thermo Fisher Scientific Inc.
  - 11.3.11.1 Company Overview
  - 11.3.11.2 Role of Thermo Fisher Scientific Inc. in the India Emerging Infectious Disease Diagnostics Market
  - 11.3.11.3 Financials
  - 11.3.11.4 Recent Developments
  - 11.3.11.5 Analyst Perspective
- 11.3.12 Siemens Healthineers AG
  - 11.3.12.1 Company Overview
  - 11.3.12.2 Role of Siemens Healthineers AG in the India Emerging Infectious Disease Diagnostics Market
  - 11.3.12.3 Financials
  - 11.3.12.4 Recent Developments
  - 11.3.12.5 Analyst Perspective
11.4 Emerging Company Snapshots
- 11.4.1 Trivitron Healthcare
  - 11.4.1.1 Company Overview
- 11.4.2 Genes2Me
  - 11.4.2.1 Company Overview
- 11.4.3 CrisprBits
  - 11.4.3.1 Company Overview
- 11.4.4 D-NOME Pvt Ltd
  - 11.4.4.1 Company Overview